OPTEL acquires Vanguard Robotics to strengthen pharma automation capabilities

OPTEL Group says it has acquired Vanguard Robotics, a specialist in end-of-line collaborative robot automation, in a move it says will reinforce its position in pharmaceutical manufacturing.

The Quebec-based company, which focuses on traceability and supply chain solutions, says the deal expands its automation capabilities at a time when workforce shortages are pushing manufacturers toward robotic systems that promise returns on investment within two years.

“This acquisition is a natural evolution of our longstanding collaboration,” said Louis Roy, founder and CEO of OPTEL. “Combining Vanguard’s expertise with our proven track-and-trace and vision systems allows us to deliver even greater value to our customers — improving line efficiency, mitigating labor constraints and boosting profitability. It aligns perfectly with our mission to empower pharmaceutical manufacturers through innovative, integrated solutions that go beyond compliance.”

Founded in 2018, Vanguard Robotics designs collaborative robotic systems for regulated pharmaceutical environments, including turnkey palletizing solutions that integrate into existing production lines.

“Joining forces with OPTEL allows us to scale our impact globally,” said Olivier Laboissionnière, co-owner of Vanguard Robotics. “Together, we’re redefining automation in pharma with faster deployment, smarter integration and a relentless focus on quality and compliance.”

The global collaborative robotics market is projected to surpass US$10 billion by 2030, growing 30 to 40 per cent annually.